<DOC>
	<DOCNO>NCT02804763</DOCNO>
	<brief_summary>The purpose evaluate efficacy safety three different dos Dapirolizumab Pegol ( DZP ) versus placebo adult subject moderately severely active systemic Lupus Erythematosus receive stable standard-of-care medication .</brief_summary>
	<brief_title>A Phase 2 Efficacy Safety Study Dapirolizumab Pegol ( DZP ) Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Clinical diagnosis Systemic Lupus Erythematosus ( SLE ) confirm SLICC classification criterion Moderate severe SLE disease activity Evidence least 1 follow SLE marker : AntidsDNA antibody confirm central laboratory Low complement confirm central laboratory Antinuclear antibody ( ANA ) titer &gt; = 1:80 combination least 1 follow : Historical positivity antidsDNA Positivity antiENA confirm central laboratory The subject receive stable SLE standardofcare medication Mixed connective tissue disease , scleroderma , and/or overlap syndrome SLE Subjects severe neuropsychiatric SLE neurological symptom opinion Investigator , would prevent subject complete protocol require procedure assessment . New worsen Class III IV lupus nephritis Chronic kidney failure stage 3b Evidence human immunodeficiency virus ( HIV ) infection , agammaglobulinemia , Tcell deficiencies , human Tcell lymphotropic virus1 infection time prior study Clinically significant active latent infection ( eg . chronic viral hepatitis B C ) Known tuberculosis ( TB ) infection , high risk acquire TB infection , latent TB ( LTB ) infection Live/live attenuate vaccine within 6 week prior first study drug infusion ( Visit 2 ) plan receive vaccine study 12 week final dose study drug History thromboembolic event within 12 month screen Subject use protocol define prohibited medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Systemic Lupus Erythematosus ( SLE )</keyword>
	<keyword>Dapirolizumab Pegol ( DZP )</keyword>
</DOC>